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Abstract
Background: This study demonstrates that a dynamic susceptibility contrast-magnetic resonance imaging (DSC-MRI)
perfusion parameter may indicate vascular abnormality in a brain tumor model and reflects an effect of dexamethasone
treatment. In addition, X-ray computed tomography (CT) measurements of vascular tortuosity and tissue markers of vascular
morphology were performed to investigate the underpinnings of tumor response to dexamethasone.
Methodology/Principal Findings: One cohort of Fisher 344 rats (N = 13), inoculated intracerebrally with 9L gliosarcoma
cells, was treated with dexamethasone (i.p. 3 mg/kg/day) for five consecutive days, and another cohort (N = 11) was treated
with equal volume of saline. Longitudinal DSC-MRI studies were performed at the first (baseline), third and fifth day of
treatments. Relative cerebral blood volume (rCBV) was significantly reduced on the third day of dexamethasone treatment
(0.656.13) as compared to the fifth day during treatment (1.266.19, p,0.05). In saline treated rats, relative CBV gradually
increased during treatment (0.896.13, 1.006.21, 1.136.23) with no significant difference on the third day of treatment
(p.0.05). In separate serial studies, microfocal X-ray CT of ex vivo brain specimens (N= 9) and immunohistochemistry for
endothelial cell marker anti-CD31 (N = 8) were performed. Vascular morphology of ex vivo rat brains from micro-CT analysis
showed hypervascular characteristics in tumors, and both vessel density (41.3262.34 branches/mm3, p,0.001) and vessel
tortuosity (p,0.05) were significantly reduced in tumors of rats treated with dexamethasone compared to saline
(74.2963.51 branches/mm3). The vascular architecture of rat brain tissue was examined with anti-CD31 antibody, and
dexamethasone treated tumor regions showed reduced vessel area (16.4561.36 mm2) as compared to saline treated tumor
regions (30.8364.31 mm2, p,0.001) and non-tumor regions (22.8061.11 mm2, p,0.01).
Conclusions/Significance: Increased vascular density and tortuosity are culprit to abnormal perfusion, which is transiently
reduced during dexamethasone treatment.
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Introduction
Blood vessels have critical role in tumor growth to deliver
nutrients and remove wastes from the tumor microenvironment.
However, tumor vessels do not adhere to the hierarchical
branching pattern of normal vessels but rather form a random
branching network with immature vessel wall [1,2]. As such, the
structure and function of the tumor’s vascular network is
considered abnormal. As a result of abnormal organization of
tumor vessels, the blood flow in tumor vessels is abnormal and
permeability of vessel is also increased [3,4].
It has been proposed, with some evidence, that abnormal blood
vessels could be pruned by eliminating excess endothelial cells,
thereby resulting to a somewhat ‘normal’ vessel state that both
functionally and morphologically can provide better delivery of
nutrients and therapeutics [2,5]. Inhibition of VEGF or its
receptor leads to apoptosis of endothelial cells and a decrease in
vessel diameter, density and permeability [1,6] and increases
oxygen tension [7]. The aforementioned changes could improve
the delivery of cytotoxic drugs or accentuate radiation therapy.
Also, the loss of VEGF dependence and the subsequent vessel
remodeling is marked by coverage of the capillaries by pericytes
[8].
Some studies have shown that a combination therapy of
antiangiogenic agent and chemotherapeutic [9,10] or radiation
therapy [7,11,12,13] produce additive or synergistic effects as
compared to either therapy alone. The hypothesis is that the
efficacy of such combined therapy is dependent on a normaliza-
tion window that is engendered by antiangiogenic agents. From
another perspective, this view of vascular normalization seems
rather counterintuitive since the normalization of tumor vascula-
ture could potentially augment the growth rate of the tumor.
Either way, understanding this process has significant implications
for improving therapeutic outcomes. If normalization provides the
best time during which treatment should be administered, it is
important to know when the normalization occurs, and how to
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optimize timing, dosing and possibly the combinations of drugs
administered. If normalization results in advanced tumor growth,
rather than a window of opportunity, treatment strategies must
avoid normalization as an endpoint. Most of the recent studies in
rodent models have been invasive, involving the measurement of
tissue parameters thought to be indicators of vascular maturity.
However, non-invasive imaging techniques can be utilized to
delineate vascular abnormality in brain tumors. In this regard, it
has been demonstrated that DSC-MRI can be used to detect a
normalization of perfusion parameters in 9L gliosarcoma tumors
treated with either dexamethasone [14] or a specific anti-
angiogenic drug [15]. Dexamethasone was shown to have anti-
angioenic effects in this rat model [14,16]. The dexamethasone
effect, as previously described [17], desensitizes tumor vessels to
VEGF and down-regulates VEGF production from 9L gliosar-
coma tumor cells. However, these measurements were performed
at just one time point, and not compared to other independent
measures of normalization. So, it was not clear whether an
inhibition or normalization event took place, and how these
changes compare to other independent measures previously used
to define normalization.
In this study, we investigated the use of DSC-MRI technique to
longitudinally monitor the evolution of the tumor microenviron-
ment before, during, and after dexamethasone treatment with the
specific goal of determining the underpinnings of abnormal
perfusion. To achieve this goal the MRI measurements of tumor
perfusion were compared to quantitative measures of vessel density
and tortuosity with microfocal computed X-ray tomography and
molecular marker of vascular morphology.
Results
DSC-MRI relative CBV measurements
Representative parametric color-coded maps from DSC-MRI
are masked over the rat brain from saline treated cohort (Figure 1)
and dexamethasone treated cohort (Figure 2) with normalized
values ranging from minimum (blue = 0) to maximum (red = 1).
These images were acquired from the same rat at the 1st (baseline),
3rd and 5th day during treatments. In these images, longitudinal
changes of tumor blood volume are clearly conspicuous within the
same rat. From these maps regions-of-interests were defined in
tumor and non-tumor regions for a cohort of rats treated with
dexamethasone (N= 13) and another cohort of rats treated with
saline (N= 11). The mean CBV value of each tumor region was
divided by the mean CBV value of the corresponding non-tumor
region. These values are reported as relative cerebral blood
volume (Figure 3A). One-way analysis of variance indicate a
significant difference of means at time points in the dexametha-
sone treated cohort (p = 0.02) whereas no significant difference was
observed in the saline treated groups (p = 0.68). Relative CBV was
significantly reduced on the 3rd day (0.656.13) of dexamethasone
treatment as compared to the 5th day (1.266.19) during treatment.
Figure 1. Representative post gadolinium-enhanced T1-weighted MR image of the same rat brain acquired longitudinally on [A] 1st
(baseline) day, [B] 3rd day, and [C] 5th day during saline treatment with corresponding parametric relative cerebral blood volume
(rCBV) maps on [D] 1st (baseline) day, [E] 3rd day, and [F] 5th day.
doi:10.1371/journal.pone.0016621.g001
DSC-MRI Surrogate Marker of Vascular Function
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In saline treated rats, relative CBV gradually increased during
treatment (0.896.13, 1.006.21, 1.136.23) with no significant
difference on the 3rd day of treatment. The increase of relative
CBV in saline-treated rats could be associated with increased
abnormal vessels in the tumor, while the transitory drop in these
measures may reflect vascular effect in tumor induced by
dexamethasone. To validate this claim, separate serial studies
were performed utilizing micro-CT and immunohistochemistry to
assess the vascular morphology and function of the dexamethasone
induced vascular effect. The tumor growth rates of the two cohorts
are shown in Figure 3B. Tumor doubling time in rat tumors
treated with dexamethasone was not substantially longer
(2.0660.34 days, r2 = 0.85) than in the saline-treated cohort
(3.1660.22 days, r2 = 0.51). Therefore, there is no substantial
growth delay of 9L gliosarcoma with dexamethasone treatment.
Vascular density and tortuosity is reduced during
dexamethasone treatment
Vascular morphology of ex vivo rat brains from micro-CT
analysis provides vessel tree skeletons (Figure 4A-B) in conjunc-
tion with 3D volume rendered X-ray images (Figure 4C-D) that
were obtained from rat brains treated with either saline or
dexamethasone. This tumor model qualitatively exhibits hyper-
vascular characteristics with a substantial increase in the total
branched vessels as compared to the same anatomical region in
the contralateral hemisphere. Vascular tortuosity was computed
from tumor regions with predefined volume-of-interest based on
tumor volume. In this context, tortuosity is defined as the
branching angle-to-length ratio in units of degree/mm between
a daughter vessel and its parent vessel. An increased vessel density
(i.e. daughter vessels) and tortuosity were profound in the tumor
regions of saline treated rats, as illustrated in figure 5. Both vessel
density (41.3262.34 branches/mm3, p,0.001) and vessel tortu-
osity (p,0.05) were significantly reduced in tumors with
dexamethasone treatment as compared to saline treatment
(74.2963.51 branches/mm3). This metric may provide an indirect
measure of vigorous vessel sprouting and its regression thereof.
Immunohistochemistry (CD31, PECAM-1) –
Morphometric analysis of tumor vessels
We examined the architecture of CD31-immunopositive vessels
to assess tumor vasculature, and response to dexamethasone
treatment. CD31-immunoreactive vessels were sparse in dexa-
methasone treated tumors where as vessels in saline treated tumors
were more conspicuous with a larger area of CD31-positive cells
(Figure 6A-B). Our results indicate that dexamethasone treat-
ment caused extensive morphological changes in vessels. In both
cohorts, vessels were more localized to dense nuclei as ascertained
from the hematoxylin stained image. Tumor vessels areas were
quantitatively analyzed on images obtained from the tumor
regions. The mean blood vessel counts per field for the
dexamethasone treated cohort was 29 whereas the mean vessel
count per field for the saline treated cohort was 16. Quantitative
analysis (Figure 7) of saline treated tumor regions revealed
Figure 2. Representative post gadolinium-enhanced T1-weighted MR image of the same rat brain acquired longitudinally on [A] 1st
(baseline) day, [B] 3rd day, and [C] 5th day during dexamethasone treatment with corresponding parametric relative cerebral blood
volume (rCBV) maps on [D] 1st (baseline) day, [E] 3rd day, and [F] 5th day.
doi:10.1371/journal.pone.0016621.g002
DSC-MRI Surrogate Marker of Vascular Function
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increased vessel area (30.8364.31 mm2, p,0.01) as compared to
non-tumor regions (22.8061.11 mm2). On the other hand,
dexamethasone treated tumor regions showed reduced vessel area
(16.4561.36 mm2) as compared to saline treated tumor regions
(30.8364.31 mm2, p,0.001) and non-tumor regions (22.806
1.11 mm2, p,0.01) (Figure 7).
Discussion
The present study sought to investigate the underpinnings of
abnormal perfusion parametric measures obtained from dynamic
susceptibility contrast-magnetic resonance imaging (DSC-MRI) in
a rat brain tumor model and to assess vascular changes after
dexamethasone treatment. It is demonstrated that parametric
measure of DSC, particularly increased relative CBV, reflects
vessel density, tortuosity, and molecular tissue marker that define
vascular abnormality in tumors. As such DSC-MRI appears to
provide a non-invasive method to characterize abnormal vascular
perfusion in longitudinal studies.
Imaging techniques that provide information about the
microvasculature have become increasingly important in recent
years. In part, this is due to the recognition that the growth of
tumor tissue is dependent on the development of new blood
vessels. Assessment of abnormal vascular perfusion using DSC-
MRI techniques was previously investigated in serial or terminal
studies [14,16,18]. The prospect of dexamethasone to induce
change in perfusion parameters of rat brain tumor was indicated at
a different time point than the current study. The experimental
designs in the previous studies [14,16] were serial studies in which
measurements were made at the end of the study. There were no
baseline and intermediate measurements within each rat brain
tumor during the treatment. Therefore, only treated group versus
untreated group can be compared. Unlike the aforementioned
serial studies, we observed in our longitudinal study a significant
earlier response to dexamethasone treatment on relative CBV
parametric measures, which is transitory.
Although, this study supports the use of DSC-MRI for
quantifying abnormal perfusion in rat brain tumors, as it is
demonstrated herein, the technique is also sensitive enough to
measuring the effect of dexamethasone treatment in the model.
This approach offers several practical advantages for integration
into other imaging protocols and to facilitate the evaluation of
potential antiangiogenic agents in pre-clinical models.
Dexamethasone treatment in the rat 9L brain tumor model can
decrease brain tumor-associated vascular permeability (VPF) by
two glucocorticoid receptor mechanisms: 1) reduction of the
response of vasculature to tumor-derived permeability factors, and
2) reduction of VPF expression by tumor cells [17]. Machein et al
demonstrated that dexamethasone downregulates the expression
of VEGF/VPF in glioma cells far less efficiently in vivo than in vitro
[19]. They showed in vitro, dexamethasone-induced downregula-
tion of VEGF was significantly higher in normoxic (50% in C6
cells and 60% in GS9L cells) than in hypoxic glioma cells (13% in
C6 and 30% in GS9L cells). Although there are several possible
explanations for the reduced potency of dexamethasone to inhibit
VEGF expression in vivo, the most likely is that a considerable
proportion of tumor cells suffer from hypoxia especially at later
stages of tumor growth. Another potential mechanism is the ability
of dexamethasone to repair blood-brain barrier dysfunction
through the inhibition of cyclooxygenase-2, which also results in
prolonged survival [20]. In addition, tumor size and vascular
density were reduced in dexamethasone treated rats implanted
with 9L gliosarcoma cells [16,21,22] and C6 glioma cells [22] after
intraperitoneal administration of 3 mg/kg/day. The mechanism
by which dexamethasone inhibits tumor growth still remains
unclear. Possible mechanisms proposed to account for such an
effect are that vessel growth may underly the mechanism by which
glucocorticoids decrease brain tumor growth [21] and that tumor
cells express glucocorticoid receptors, which makes them the
primary target [22].
In collating our findings, it is demonstrated that the vascular
density and tortuosity are culprit to abnormal perfusion measure-
ments obtained from longitudinal studies with the utility of DSC-
MRI. Parametric measure of this technique, relative CBV, is a
potential non-invasive marker for assessing pathological states of
vessel attributes in brain tumor.
Materials and Methods
Animal Preparation
All procedures with animals were performed in accordance with
the recommendations in the guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. Our
protocol (AUA00000349) was approved by the Institutional
Animal Care and Use Committee (IACUC) of the Medical
College of Wisconsin (Animal Welfare Assurance No. A3102-01).
The 9L cells (MGH, Boston, MA) were cultured and propagated
Figure 3. Longitudinal results of [A] quantitative relative
cerebral blood volume (rCBV) values of saline treated (N=11)
and dexamethasone treated (N=13) cohorts in vivo, and [B]
tumor growth rate. Data points are displayed as mean6SEM, and the
p-values were evaluated by one-way ANOVA (nsp-value.0.05,
*p-value#0.05, ** p-value#0.01, *** p-value#0.001).
doi:10.1371/journal.pone.0016621.g003
DSC-MRI Surrogate Marker of Vascular Function
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in Dulbecco’s modified Eagle’s minimum essential medium with
4.5 g/L glucose, 90% 1 mM sodium pyruvate, and 10% fetal
bovine serum (GIBCO BRL, Gaithersburg, MD). A total of thirty-
four Fisher 344 adult male rats (Sprague Dawley, Harlan,
Indianapolis) weighing 250-300 g were anesthetized by an
intraperitoneal (i.p.) injection of 0.1 mL/kg of ketamine cocktail
made from 1.8 mL of xylazine (20 mg/kg), 3.6 mL of ketamine
hydrochloride (200 mg/kg), and 0.6 mL of acepromazine (3 mg/
kg). The rat scalps were shaved and wiped with antiseptic swab.
Under aseptic conditions, each rat was placed in a stereotaxic head
frame (Kopf Instruments, Tujunga, CA), a minor incision was
made along the midline, and a 0.15 mm burr hole was drilled at
2 mm to the right of the sagittal suture and 1 mm anterior to the
bregma. Approximately 10 mL of medium containing 105 9L
gliosarcoma cells was slowly injected to a depth of 3 mm with a
gas-tight syringe (Hamilton, Reno, NV) over a 5-minute period.
The 26-gauge needle was slowly withdrawn to prevent extrusion of
these cells. Finally, the incision was closed with surgical staple. The
animals were returned to their cages and given food and water ad
libitum. We allowed the tumors to grow up to 14 days post-
inoculation before treatment. Tumor volume measurements were
obtained from post gadolinium-enhanced T1-weighted MR
images. Data from tumor volume measurements were fitted to
an exponential growth rate, y = y06e
(kt), with nonlinear regression
implementing least squares method where y is the tumor volume
(mm3), yo is the measured volume at the start of MRS experiment,
k is the rate constant, and t is the time (day). Tumor doubling time
was calculated as 0.69/k.
Dynamic Susceptibility Contrast-Magnetic Resonance
(DSC-MR) Imaging
In the longitudinal experiment one cohort (N= 13) was treated
(i.p.) with 3 mg/kg per day of dexamethasone sodium phosphate
(American Regent Laboratories Inc., Shirley, NY) for five
consecutive days, and another cohort (N= 11) was given equal
volume of saline. Each rat was anesthetized with injection (i.p.) of
the ketamine cocktail previously described and monitored for
respiration (6066 breath/min) and temperature (376.5uC) during
all MRI experiments. All MRI studies were performed using a
clinical 3.0 Tesla SignaTM Excite system (GE Healthcare,
Waukesha, WI). A quadrature birdcage coil was used for
radiofrequency transmission and reception. Echo planar imaging
(EPI) was used for acquiring axial DSC images of multiple sections
with a temporal resolution of 1020 millisecond. The MR protocol
included using a GRE (Gradient Recalled Echo)-EPI sequence
(TR: 1 s, TE: 34.5 ms, FOV: 4 cm, Matrix: 64664, Slice
thickness: 2 mm, 0.2 mm spacing, slices = 5). The GRE-EPI data
was acquired for a total of 120 seconds before, during and after
bolus injection of 2.5 mgFe+3/kg monocrystalline iron oxide
nanoparticle (MION) (Center for Molecular Imaging Research,
Charleston, MA), an intravascular susceptibility contrast agent
[23,24], administered through a permanent-catheter implanted
Figure 4. Qualitative morphology from micro-CT data of representative ex vivo rat brains. Top view of vessel tree skeleton in [A] saline
treated rat and [B] dexamethasone treated rat. Side view of 3D volume rendered image of [C] saline treated rat and [D] dexamethasone treated rat.
doi:10.1371/journal.pone.0016621.g004
DSC-MRI Surrogate Marker of Vascular Function
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within a femoral vein. MRI experiments were performed on each
rat on the 1st (baseline), 3rd, and 5th day of treatments.
Programs were developed in-house using Red Hat Linux and
Analysis of Functional Neuro-Images (AFNI) software for post-
processing of the MRI data. Tracer kinetics analysis was used to
compute the perfusion parameters as described previously
[14,15,25]. Succinctly, cerebral blood volume (CBV) measure-
ments were obtained by integrating the area under the transverse
relaxation time curves (i.e. DR2*). Next, the interactive AFNI draw
dataset plugin was used to manually segment the brain from the
surrounding tissue, as illustrated in Figure 1A-C, and the color-
coded fit parameters were thresholded at Pthr = 2.6*10-6, which
corresponds to a Bonferroni corrected a=0.05. Regions of interest
(ROI) were chosen as: untreated tumor, untreated contralateral
side, dexamethasone-treated tumor, and dexamethasone-treated
contralateral side. Two ROIs were selected in the slice with the
largest tumor cross-section. The first ROI was located in the well-
delineated contrast enhancing area of the tumor, and the second
ROI was located in an area contralateral to the tumor. The mean
value of the tumor region was normalized to the mean value of the
Figure 5. Quantitative morphology from micro-CT data of ex
vivo rat brains. [A] Density of vessel branches in tumor volume of
interest for saline treated (N= 4) and dexamethasone treated (N= 5)
rats. All bar graphs are displayed as mean6SEM, and the p-value
was evaluated by unpaired t-test (*p-value #0.05, ** p-value #0.01,
*** p-value #0.001). [B] Histogram of tortuosity in saline treated (N= 4)
and dexamethasone treated (N= 5) rats. The p-value was evaluated by
Mann Whitney U test (p,0.05).
doi:10.1371/journal.pone.0016621.g005
Figure 6. Immunohistochemistry of vessels (anti-CD31, brown)
and cell nuclei (hematoxylin, blue) from rat 9L gliosarcoma
brain tissue with 0.26 mm2 field-of-view at 206magnification.
Tumor regions of [A] saline treated and [B] dexamethasone treated rats.
doi:10.1371/journal.pone.0016621.g006
Figure 7. Mean vessel area from anti-CD31 photomicrographs
of saline treated (N=4) rats and dexamethasone treated (N=4)
rats. All bar graphs are displayed as mean6SEM, and the p-values
were evaluated by unpaired t-test (*p-value #0.05, ** p-value #0.01,
*** p-value #0.001).
doi:10.1371/journal.pone.0016621.g007
DSC-MRI Surrogate Marker of Vascular Function
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corresponding contralateral side. Finally, Gadodiamide
(0.2 mmol/kg, Omniscan, Nycomed, Princeton, NJ) was injected
via the femoral vein to acquire a high-resolution, post-contrast T1-
weighted spin echo, image (TE/TR: 12 ms/450 ms; ma-
trix = 2566256; NEX=16, slices = 5). One-way analysis of
variance (ANOVA) was performed on each cohort followed by a
Bonferroni post test to compare all pairs of time points at a
significance level of alpha= 0.5 (95% confidence intervals).
Statistical analysis was performed using GraphPad Prism version
4.0a for Mac OS X (GraphPad Software, San Diego, California
USA).
Microfocal X-ray Computed Tomography Technique
To study the vascular tortuosity of 9L gliosarcoma tumor,
microfocal X-ray computed tomography (CT) was used to study
nine additional rats, also inoculated with 9L gliosarcoma cells. Of
these, five were treated with dexamethasone according to the same
protocol described in the DSC section. On the 3rd day of
treatments, the time of treatment effect, MRI was performed and
brain specimens were further analyzed to validate vessel
morphology. For these studies, both carotid arteries were
catheterized and infused with a barium sulfate medium (10 ml
saline +1 g gelatin +10 g Ba2SO4) for X-ray contrast. The
methods for CT imaging and data analysis have been previously
described [26,27]. Briefly, the CT system is composed of an X-ray
source (model Fein-Focus-100.50) with a 3-mm focal spot, a North
American Imaging AI-5830-HP image intensifier coupled to a
Silicon Mountain Design charged-coupled device camera, and a
New England Affiliated specimen micro-manipulator stage
mounted on a precision rail, with position information provided
by Mitutoyo linear encoders. Image acquisition parameters were
as follow: 41 kV, 140 mA, 5u half-cone beam angle, 18.05 cm
source-to-object distance, and 78.88 cm source-to-detector dis-
tance, 50 frames were averaged for each of the 360 planar
acquired at 1u rotational increments. Projection images were
carefully preprocessed to compensate for distortions introduced by
imaging chain [26,27]. The Feldkamp [28,29] cone-beam
algorithm was implemented to yield a matrix of 49764976497
voxels representing a volume of 2.2562.2562.25 cm3 giving an
isotropic resolution of 45.19 mm. Morphometric analysis was
performed on the reconstructed images using the Tree module of
Analyze 6.1 [30,31,32]. The Tree module analysis generates a
skeleton of the vessel structure and computes branching angles,
segments lengths, and cross-sectional area, which depict the vessel
attributes. Volume of interests (VOI) was based on the estimated
tumor volume from T1-weighted MR images, and centered at an
anatomical landmark in reference to the inoculation coordinates.
Vessel density for each VOI was computed as the number of
branched vessels to VOI in units of branches/mm3. Tortuosity,
defined as the branching angle-to-length ratio in units of degrees/
mm, was determined for each region. Statistical analysis was
performed using GraphPad Prism version 4.0a for Mac OS X
(GraphPad Software, San Diego, CA). The Student unpaired t-test
and Mann-Whitney test were performed to compare the density
and tortuosity of vessels in untreated control rats to dexametha-
sone-treated rats, respectively.
Immunohistochemistry (CD31, PECAM-1) –
Morphometric analysis of tumor vessels
In a separate serial study (N= 4 saline, N= 4 treated) MRI was
performed on the 3rd day of treatment, the time of treatment
effect, and the tumor-inoculated rat brain was snap-frozen in
liquid isopentane chilled on dry ice, and the brain was overlaid
with Tissue-Tek embedding matrix (O.C.T. compound, Sakura
Finetek U.S.A, Inc., Torrance, CA) and stored at -80uC. The
O.C.T covered brain was sliced into 6 mm sections in a cryostat
(Cryocut 1800, Reichert-Jung) cooled to –20uC. Brain sections
were fixed in cold acetone (–20uC) for two minutes and rinsed with
Tris-buffer saline to remove frozen O.C.T. compound. Sections
were incubated with 1.5% H2O2 in methanol for ten minutes and
rinsed twice with TBS. Sections were incubated subsequently with
1% horse serum in TBS. Immunohistochemistry was performed
on 6 microns thick slices that were obtained from the extracted rat
brains. To examine the vascularity of the tumor regions purified
mouse anti-rat CD31 monoclonal antibody (BD PharMingen, San
Diego, CA) was used as a primary antibody to stain for platelet
endothelial cell adhesion molecule-1 (PECAM-1). Avidin and
Biotin blocking kit (VECTOR, Burlingame, CA) solutions were
used as recommended by the manufacturer’s procedure. All
sections were rinsed three times with distilled water for five
minutes. These slides were later counterstained with Hematoxylin
(Gill’s formula, VECTOR, Burlingame, CA) according to the
manufacturer’s protocol. The histological slices were imaged with
106and 206objective lenses at a light microscope, Nikon Model
E-400 SPOT Insight Color Camera (Diagnostic Instrument Inc.,
Sterling Heights, Michigan). These images were further processed
in MetaMorph version 6.2 (Universal Imaging Co., Downington,
Pennsylvania, PA) to compute the number of vessels and their
respective cross sectional area. An unpaired student’s t-Test was
performed to compare the mean vessel area of untreated control
rats and dexamethasone treated rats using GraphPad Prism
version 4.0a for Mac OS X (GraphPad Software, San Diego, CA).
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